問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

List

1336Cases

2018-09-01 - 2022-05-25

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 2

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Mirikizumab

Participate Sites
12Sites

Recruiting10Sites

Terminated1Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2019-08-09 - 2022-06-30

Phase III

A Phase 3, Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis

  • Condition/Disease

    Secondary Hyperparathyroidism

  • Test Drug

    KHK7580

Participate Sites
10Sites

Terminated10Sites

唐德成
Taipei Veterans General Hospital

Division of Nephrology

2018-10-01 - 2026-12-31

Phase III

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS

  • Condition/Disease

    FOCAL SEGMENTAL GLOMERULOSCLEROSIS

  • Test Drug

    Sparsentan

Participate Sites
12Sites

Recruiting11Sites

Terminated1Sites

2019-02-01 - 2023-08-04

Phase III

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

  • Condition/Disease

    Breast Cancer

  • Test Drug

    trastuzumab deruxtecan (T-DXd)

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-11-15 - 2024-03-15

Phase I

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

  • Condition/Disease

    Small Cell Lung Carcinoma

  • Test Drug

    AMG 757

Participate Sites
3Sites

Recruiting3Sites

2021-09-02 - 2026-05-25

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-01-01 - 2025-08-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

陳宜君
National Taiwan University Hospital

Division of Infectious Disease

2021-11-01 - 2024-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2028-01-24

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-07-21 - 2023-03-29

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 102 103 104 105 106 134
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB